Our results demonstrates that Lfcin significantly enables HAdV-C5 infection/transduction of both proliferating myoblasts (Fig. 1) and terminally differentiated myotubes (Fig. 2), which suggests that inclusion of Lfcin can be useful for clinical applications of HAdV-C5-based vectors targeting. The gene discussed is C5; the disease is infection.